IceCure Medical Ltd (ICCM)

NCM – Цена в реальном времени. Валюта: USD

5.96

-1.06 (-15.10%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

5.90

-0.06 (-1.01%)

После закрытия: Jun 26, 2026, 7:55 PM EDT

02.06.2026

IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance

Proactive Step to Regain Nasdaq Compliance as Part of the Company's Broader Capital Markets Strategy CAESAREA, ISRAEL, June 2, 2026 /PRNewswire/ -- IceCure Medical Ltd. (the "Company" or "IceCure" or "IceCure Medical") (NASDAQ: ICCM), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it intends to effect a one-for-thirty reverse split (the "Reverse Share Split") of the Company's ordinary shares, no par value per share, (the "Ordinary Shares"), as part of its proactive efforts to regain compliance with the Nasdaq $1.00 minimum bid price requirement and support its broader capital markets strategy.

19.05.2026

IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked

At the annual European Conference on Interventional Oncology, ICESECRET data presented demonstrated 89.4% recurrence-free rate in patients with tumors ≤3 cm and 83.9% of patients remained recurrence-free at a median follow-up of 4.0 years Independent breast cancer study reported no residual cancer at 6 and 12 months post-procedure, with 100% of patients reporting excellent cosmetic outcomes Independent study showed 92.9% reduction in fibroadenoma volume at 12 months post-treatment with ProSense® FDA clearance of ProSense® in early-stage breast cancer drives expanding global adoption and clinical interest in breast cryoablation CAESAREA, Israel, May 19, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that cryoablation and ProSense® were featured at the annual European Conference on Interventional Oncology ("ECIO") 2026, held in Basel, Switzerland on April 26 to 30, 2026.

13.05.2026

IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

No Immediate Effect on Nasdaq Listing or Trading of the Company's Ordinary Shares CAESAREA, Israel, May 13, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it has received a notification letter from Nasdaq Stock Market LLC ("Nasdaq") that the Company has been granted an additional 180-day compliance period, or until November 9, 2026 to regain compliance with Nasdaq's minimum bid price rule.

12.05.2026

IceCure Medical Ltd (ICCM) Q1 2026 Earnings Call Transcript

12.05.2026

IceCure Medical Ltd. (ICCM) Reports Q1 Loss, Lags Revenue Estimates

IceCure Medical Ltd. (ICCM) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.03.

12.05.2026

IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America

Pent-up demand immediately following FDA clearance generates 46% increase in active customer accounts using ProSense® as of the end of the first quarter 2026, compared with prior to FDA clearance Accelerating adoption of ProSense® driven by several growth catalysts, including FDA clearance, expanding reimbursement framework, media coverage, growing body of clinical data and recommendation of cryoablation for breast cancer in leading clinical guidelines Conference call to be held today at 11:00 am Eastern Time CAESAREA, Israel, May 12, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today reported financial results as of and for the three months ended March 31, 2026 as well as recent commercial and clinical updates.

06.05.2026

IceCure Medical to Report First Quarter 2026 Financial and Operating Results on May 12, 2026

CAESAREA, Israel, May 6, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the three months ended March 31, 2026 before the Nasdaq Stock Market opens on Tuesday, May 12, 2026.

Видео

No Data

There is no data to display

Пресс-релизы

02.06.2026

IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance

19.05.2026

IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked

13.05.2026

IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

12.05.2026

IceCure Medical Ltd (ICCM)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

IceCure Medical Ltd (ICCM)

IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance

IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked

IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

IceCure Medical Ltd (ICCM) Q1 2026 Earnings Call Transcript

IceCure Medical Ltd. (ICCM) Reports Q1 Loss, Lags Revenue Estimates

IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America

IceCure Medical to Report First Quarter 2026 Financial and Operating Results on May 12, 2026

Видео

No Data

Пресс-релизы

IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance

IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked

IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America

IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance

IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked

IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

IceCure Medical Ltd (ICCM) Q1 2026 Earnings Call Transcript

IceCure Medical Ltd. (ICCM) Reports Q1 Loss, Lags Revenue Estimates

IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America

IceCure Medical to Report First Quarter 2026 Financial and Operating Results on May 12, 2026

Видео

No Data

Пресс-релизы

IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance

IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked

IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America

Search stocks

IceCure Medical Ltd (ICCM)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

IceCure Medical Ltd (ICCM)

IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance

IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked

IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

IceCure Medical Ltd (ICCM) Q1 2026 Earnings Call Transcript

IceCure Medical Ltd. (ICCM) Reports Q1 Loss, Lags Revenue Estimates

IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America

IceCure Medical to Report First Quarter 2026 Financial and Operating Results on May 12, 2026

Видео

No Data

Пресс-релизы

IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance

IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked

IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America

IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance

IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked

IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

IceCure Medical Ltd (ICCM) Q1 2026 Earnings Call Transcript

IceCure Medical Ltd. (ICCM) Reports Q1 Loss, Lags Revenue Estimates

IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America

IceCure Medical to Report First Quarter 2026 Financial and Operating Results on May 12, 2026

Видео

No Data

Пресс-релизы

IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance

IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked

IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America